Kasim Kutay

Kasim Kutay (born 13 May 1965) is the CEO of Novo Holdings A/S, an investment fund that manages investments and assets for the Novo Nordisk Foundation. He holds British citizenship.

Kasim Kutay
Born (1965-05-13) May 13, 1965
Alexandria, Egypt
CitizenshipUnited Kingdom
EducationBSc. and MSc. - London School of Economics
EmployerMorgan Stanley (1989-2007)

Sun Group (2007-2009) Moelis & Company (2009-2016)

Novo Holdings A/S (2016 - Present)
Title
Board member of
Spouse(s)Maha Arakji Kutay

Novo Holdings is one of the largest life science investors in the US and Europe, managing assets worth approximately DKK 400 billion Danish Kroners[1][2] (approximately $60bn).[2]

Kasim Kutay is a former investment banker, focusing on the healthcare sector.[3] Kasim Kutay assumed the role of CEO at Novo Holdings A/S on September 1, 2016, following the departure of Eivind Kolding.[4]

Kasim Kutay joined Novo Holdings A/S after more than two decades working within investment banking.

He began his career at the investment bank Morgan Stanley in 1989, rising to the post of chairman of its European Healthcare Group.[4] After 18 years at Morgan Stanley, Kasim Kutay worked at a private US investment firm, Sun Group,[2] prior to joining Moelis & Company in 2009.

He joined Moelis & Company in 2009, where he worked for seven years, serving as Co-head of Europe and member of its Management Committee until he joined Novo Holdings A/S in 2016.[5][3]

Kasim Kutay is a member of the Board of Directors at Novozymes,[6][7] Novo Nordisk A/S,[8] Evotec SE[9] and a former board member of ConvaTec up until July 3 - 2018.[10][11]

Kasim Kutay is also a charity board member of the Chelsea and Westminister NHS Foundation Trust.[2]


Education

Kasim Kutay holds a BSc in Economics and an MSc in Politics of the World Economy, both from the LSE (London School of Economics and Political Science).

Prior to studying at LSE (London School of Economics and Political Science), Kasim Kutay went to the American Community School in London.[2]

Early life and career

Kasim Kutay is a citizen of the United Kingdom. He was born in Alexandria, Egypt on 13 May 1965 to a Turkish father and Syrian mother.[2]

The family moved to Lebanon until the Lebanese Civil War broke out in 1975 where the family relocated to London, United Kingdom.[2]

He studied at the London School of Economics and Political Science, where he attained his Master of Science in Economics in 1987.

Kasim Kutay began his career, with his first job as a graduate trainee at Morgan Stanley[12] in 1989.[2] Kasim Kutay spent 18 years at Morgan Stanley advising mainly healthcare companies.[13]

He joined Moelis & Company in 2009, where he served as Co-head of Europe and member of its Management Committee until he joined Novo Holdings A/S in 2016.[5][3]

Novo Holdings A/S

Kasim Kutay was appointed CEO of Novo Holdings A/S in June 2016, succeeding Eivind Kolding.

Kasim Kutay was very familiar to Novo Holdings A/S before assuming the role of CEO, having previously advised the company over many years on both disposals and acquisitions. He has also advised several other Danish healthcare companies including William Demant and Lundbeck.[1]

Novo Holdings A/S manages approximately DKK 400 billion Danish Kroners[1][2] (approximately $60bn)[2] worth of assets.

Personal life

Kasim Kutay currently resides in Denmark and is married to architect Maha Arakji Kutay.[2]

The couple have three children.

References
  1. https://www.bloomberg.com/news/articles/2016-06-21/investment-firm-novo-names-moelis-s-kutay-as-new-chief-executive
  2. Meddings, Sabah (2018-11-04). "Interview: biotech boss Kasim Kutay is investing billions — according to Jante". The Sunday Times. ISSN 0956-1382. Retrieved 2018-12-10.
  3. http://www.novo.dk/sites/default/files/images/pdf/novo_as_appoints_kasim_kutay_as_new_ceo_210616.pdf
  4. "After ousting former CEO, Novo A/S puts Kutay in charge of $57B investment vehicle - FierceBiotech". Retrieved 5 March 2017.
  5. http://www.pharmatimes.com/appointments/novo_as_appoints_new_ceo_1045521
  6. "Board of Directors in Novozymes". Retrieved 5 March 2017.
  7. "The Novo Team - Novo A/S". Retrieved 5 March 2017.
  8. http://www.novonordisk.com/about-novo-nordisk/management/board_of_directors/kasim-kutay.html
  9. https://www.evotec.com/en/invest/news--announcements/p/evotec-se-virtual-annual-general-meeting-2020-approves-all-proposed-agenda-items-5947
  10. "03 July 2018 - Board Changes | ConvaTec Group". convatecgroup.com. Retrieved 2018-11-29.
  11. https://www.convatecgroup.com/media/1259/convatec-proposed-directorate-changes.pdf
  12. Meddings, Sabah (2018-11-04). "Interview: biotech boss Kasim Kutay is investing billions — according to Jante". The Sunday Times. ISSN 0956-1382. Retrieved 2018-12-10.
  13. "Kasim Kutay: Executive Profile & Biography - Bloomberg". Retrieved 5 March 2017.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.